Your browser does not support JavaScript! Vetoryl Capsules for Dog - 1 x 60mg |
Skip to content Skip to navigation menu
Product Matches
You have setup the following Repeat Order:
Delivered every:
Vetoryl Capsules for Dog
Vetoryl Capsules for Dog
Vetoryl Capsules for Dog
Uses Vetoryl capsules are a veterinary-prescribed treatment for Cushing’s syndrome in dogs. How it works Vetoryl capsules can be used to treat adrenal-based and pituitary-based Cushing’s...  Read more

Vetoryl Capsules for Dog

Sorry, this product is out of stock right now
Make sure you get what you need for your pet.
View products with the same criteria that are  in stock:
You can also create a stock alert and we'll let you know as soon as it's available again.

Please sign in to add this to your favourites

Back in stock notification
Vetoryl Capsules for Dog
Vetoryl Capsules for Dog
Vetoryl Capsules for Dog
Enter your name and email address below then select which items you would like to be notified of when available.
Notify me when item is in stock

Product details


Vetoryl capsules are a veterinary-prescribed treatment for Cushing’s syndrome in dogs.

How it works

Vetoryl capsules can be used to treat adrenal-based and pituitary-based Cushing’s disease in your dog, giving them a happier, healthier quality of life. Cushing’s disease is the overproduction of the hormone cortisol which leads to issues such as hair loss and increased appetite and drinking. An excessive amount of cortisol can supress your dog’s immune system, leaving them vulnerable to bacterial infections and illness.

This medicine's main active ingredient is trilostane – a steroid that reduces the production of cortisol in dogs. With continued use, the complications from excess levels of cortisol are reduced. With lower cortisol levels, you should soon see that your dog has a fuller, healthier coat, a more normal appetite and greater control of their bladder.

The capsules are administered orally. Giving it to your dog in the morning with food can help them to absorb it more easily.

Key benefits

• Vetoryl can be used daily to help control Cushing’s disease
• contains the steroid trilostane to block the over-production of cortisol
• once cortisol levels are reduced, your pet’s immune system will begin to repair
• orally administered capsules are available in different strengths
• should only be used with a prescription

When to use it

Vetoryl requires a prescription and should only be administered under the direction of your vet after an examination and diagnosis has taken place. Cushing’s syndrome requires daily treatment to ensure your dog is as healthy as possible. Work treatment into their daily feeding routine and try to make sure you’re giving them their medicine at the same time each day. It’s important to monitor your dog’s reaction to their medicine in the first few weeks – if you see any negative effects such as vomiting or diarrhoea, consult your vet straight away.

For oral administration to dogs.
Information for the animal owner:
Follow the dosage instructions given by your veterinary surgeon. In clinical studies, an average starting dose of 6 mg/kg once daily was effective; however, the dose should be adjusted according to individual response, as determined by monitoring by your veterinary surgeon. Most dogs were eventually stabilised on doses between 2-10 mg/kg/day. Administer orally, once daily, with food. Dosing in the morning is preferable as this will allow your veterinary surgeon to perform monitoring tests 4-6 hours following administration of the dose.
Do not divide or open capsules.

The dose should then be titrated according to individual response as determined by monitoring.
Should symptoms not be adequately controlled for an entire 24 hour inter-dose period, consideration should be given to increasing the daily dose by as small an increment as possible and dividing it between morning and evening doses. A small number of animals may require doses significantly in excess of 10 mg per kg bodyweight per day. In these situations appropriate additional monitoring should be implemented.
10 mg capsules should be used in dogs that require particularly small doses of Trilostane, and to assist with dosage adjustments.
Where there is no apparent response to treatment, the diagnosis should be re-evaluated. Dose increases may be necessary. Do not use in dogs weighing less than 3 kg.
Monitoring: Samples should be taken for biochemistry (including electrolytes) and an ACTH stimulation test pre-treatment and then at 10 days, 4 weeks, 12 weeks, and thereafter every 3 months, following initial diagnosis and after each dose adjustment. It is imperative that ACTH stimulation tests are performed 4-6 hours post-dosing to enable accurate interpretation of results.
Regular assessment of the clinical progress of the disease should also be made at each of the above time points.
Do not use in animals suffering from liver disease and/or poor kidney function.

Adverse reactions:
(Information for the animal owner) If your dog becomes lethargic, develops vomiting or diarrhoea, or has a depressed appetite, stop treatment and consult your veterinary surgeon.
If you notice any serious effects or other effects not mentioned in the leaflet, please inform your veterinary surgeon.
(Information for the veterinary surgeon) Corticosteroid withdrawal syndrome or hypocortisolaemia should be distinguished from hypoadrenocorticism by evaluation of serum electrolytes.
Signs associated with iatrogenic hypoadrenocorticism, including weakness, lethargy, anorexia, vomiting and diarrhoea may occur, particularly if monitoring is not adequate. Signs are generally reversible within a variable period following withdrawal of treatment. Acute Addisonian crisis (collapse) may also occur. Lethargy, vomiting, diarrhoea and anorexia have been seen in dogs treated with Trilostane in the absence of evidence of hypoadrenocorticism.
There have been occasional isolated reports of adrenal necrosis in treated dogs which may result in hypoadrenocorticism.
Subclinical renal dysfunction may be unmasked by treatment with the product.
Treatment may unmask arthritis due to a reduction in endogenous corticosteroid levels.
A small number of reports have been received of sudden death during Trilostane treatment.
Other mild, rare, adverse effects include ataxia, hypersalivation, bloating, muscle tremors and skin changes.

Special warnings:
(Information for the animal owner) If your dog is being treated with any other medications advise your veterinary surgeon prior to the use of Vetoryl.
Do not use in pregnant or nursing bitches or in any animals intended for breeding.
Tell your veterinary surgeon if your dog is suffering from concurrent illnesses, especially liver disease, kidney disease, anaemia or diabetes mellitus.
Tell your veterinary surgeon if you intend to breed from your dog or your dog is pregnant or nursing.
(Information for the veterinary surgeon) The product should be used with extreme caution in dogs with pre-existing anaemia as further reductions in packed-cell volume and haemoglobin may occur. Regular monitoring should be undertaken.
As the majority of cases of hyperadrenocorticism are diagnosed in dogs between the ages of 10-15 years, other pathological processes are frequently present. It is particularly important to screen cases for primary hepatic disease and renal insufficiency as the product is contraindicated in these cases.
Dogs should be monitored at regular intervals for diabetes mellitus. The presence of diabetes mellitus and hyperadrenocorticism together requires specific monitoring.
If a dog has previously been treated with Mitotane, its adrenal function will have been reduced. Experience in the field suggests that an interval of at least one month should elapse between cessation of Mitotane and the introduction of Trilostane. Close monitoring of adrenal function is advised, as dogs may be more susceptible to the effects of Trilostane.
Close monitoring during treatment should be carried out. Particular attention should be paid to liver enzymes, electrolytes, urea and creatinine.
In the event of a non-stimulatory ACTH stimulation test during monitoring, treatment should be stopped for 7 days and then re-started at a lower dose. Repeat the ACTH stimulation test after a further 14 days. If the result is still non-stimulatory, stop treatment until clinical signs of hyperadrenocorticism recur. Repeat the ACTH stimulation test one month after re-starting treatment.
Interactions: The possibility of interactions with other medicinal products has not been specifically studied. Given that hyperadrenocorticism tends to occur in older dogs, many will be receiving concurrent medication.
In clinical studies, no interactions were observed. The risk of hyperkalaemia developing should be considered if Trilostane is used in conjunction with potassium-sparing diuretics or ACE inhibitors. The concurrent use of such drugs should be subject to a risk-benefit analysis by the veterinary surgeon, as there have been a few reports of deaths (including sudden death) in dogs when treated concurrently with Trilostane and an ACE inhibitor.
(Information for the animal owner) If an overdose of the product is given consult your veterinary surgeon immediately.
(Information for the veterinary surgeon) Overdose may lead to signs of hypoadrenocorticism. There were no mortalities following chronic administration at 3 x the maximum recommended dose to healthy dogs, however mortalities may be expected if higher doses are administered to dogs with hyperadrenocorticism. There is no specific antidote for Trilostane. Treatment should be withdrawn and supportive therapy, including corticosteroids, correction of electrolyte imbalances and fluid therapy may be indicated depending on clinical signs.
In cases of acute overdosage, induction of emesis followed by administration of activated charcoal may be beneficial.
Any iatrogenic adrenocortical insufficiency is usually quickly reversed following cessation of treatment. However in a small percentage of dogs, effects may be prolonged. Symptomatic treatment or appropriate replacement therapy should be initiated. Following a one week withdrawal of Trilostane treatment, treatment should be reinstated at a reduced dose rate.
Symptomatic treatment of hypocortisolaemia may be required.
Operator warnings: Trilostane may decrease testosterone synthesis and has anti-progesterone properties.
Women who are pregnant or are trying to become pregnant should avoid handling the capsules.
Wash hands with soap and water following accidental exposure and after use.
The content of the capsules may cause skin and eye irritation and sensitisation. Do not divide or open capsules: in the event of accidental breakage of the capsules and contact of the granules with the eyes or skin, wash immediately with plenty of water. If irritation persists, seek medical advice.
In the event of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the physician.
People with known hypersensitivity to Trilostane or any of the excipients should avoid contact with the product.

Customer reviews

4.8 out of 5 80  Reviews

Product reviews are filtered by language.
The following reviews are available in English. 

  • Vetoryl Capsules
    Have been ordering this product for some time now. Fast and efficient service . Great value and a Lot cheaper than buying from vets. Never had any problems. Definitely recommend .
    Elizabeth Pendlington - June 20, 2017
  • Vetoryl capsules
    Have been ordering this product for some time now , always fast and efficient service and well packaged , would recommend .
    Elaine woolhead - May 23, 2017
  • Vetoryl capsules
    Have been ordering this product for some time now , always fast and efficient service and well packaged , would recommend .
    Elaine woolhead - May 23, 2017
  • Evaluation
    Tres bien produit et delais de livraison
    Leger - March 16, 2017
  • Vetoryl
    Olie, our little dashhound, who is 12 years old has Cushings Disease. I have found Petmeds to be very efficient, prompt and helpful with the delivery of their medicines and will definitely recommend them. Thank you
    Graham Hardey - February 17, 2017